Chronic pain trial ‘strategically important’

The Guild is encouraging pharmacists to increase patient recruitment numbers for the Chronic Pain MedsCheck Trial

In this week’s edition of Forefront, the Guild reminded participating pharmacists that patient recruitment ends on 30 September 2019 – meaning there is just over three more weeks for pharmacies to recruit them and conduct the initial services.

“The trial uses a pharmacist-led, patient-centred service to support patients who are taking medicines to manage chronic pain, or who are self-managing or experiencing pain medicine dependency issues,” the Guild says.

“The trial provides an opportunity to cement the role that community pharmacies already play in identifying and helping our patients manage chronic pain and in primary healthcare.”

In a message to Guild members last week, national president George Tambassis said he strongly encouraged members to “make a push” for more participating patients.

“This trial is strategically important for community pharmacy because it provides an opportunity to cement the role of community pharmacies in primary health care,” he wrote.

“The outcomes of this trial may inform the assessment of whether a national chronic pain program through community pharmacy can be implemented.

“It is vital that as many pharmacies as possible recruit patients and provide the trial service according to the required protocol.

“The better the quality of our data, the stronger the case will be for increasing the role of pharmacy in chronic pain management and primary health care.”

The Guild reminded pharmacists that to be eligible, patients must be:

  • Adults who are 18 years and over
  • Have a Medicare and/or DVA card
  • Taking over the counter (e.g. ibuprofen or paracetamol) or prescription medicine to treat pain that has been present for three months or greater
  • Based on patient self-report, have not received a MedsCheck or HMR in the previous 12 months
  • In the pharmacist’s opinion, there is an opportunity to improve self-management or address dependency concerns.

More information is available about the trial at or via the Chronic Pain MedsCheck Trial team on 1300 555 262 or via email at

Previous More GPs to integrate a pharmacist
Next Don’t allow CWH monopoly: Guild

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

1 Comment

  1. Ex-Pharmacist

    The “Chronic Pain MedsCheck Trial” is nothing more than financial compensation extracted from the Federal Government by the Pharmacy Guild of Australia for the up-scheduling of Codeine. $20 Million cash from Australian taxpayers to greedy pharmacy owners who are predominately Guild members.


Leave a reply